Cryoport Inc (CYRX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CYRX SEC filings page.
Cryoport Inc (CYRX) reported $186.5M in revenue over the twelve months to Jun 30, 2026, up 12.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cryoport’s 2025 rebound is driven by margin and cost improvement, but cash conversion still trails reported earnings.
FY2025’s reported-profit rebound did not translate into operating cash: net income was$78.3M while operating cash flow was-$8.6M . With free cash flow still-$25.0M , the positive bottom line was not matched by cash generation from ongoing operations, pointing to a meaningful earnings-quality gap.
Revenue recovered
The liquidity profile tightened even as the measured leverage ratio improved: current ratio fell from 5.3x in FY2024 to 2.2x in FY2025. Debt-to-equity declined from 0.8x to 0.5x, but current liabilities rose to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cryoport Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cryoport Inc held $411.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $8.6M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Cryoport Inc scores 99/100 among other emerging companies.
Cryoport Inc had 50M shares outstanding at the end of fiscal year 2025, against 50M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Cryoport Inc scores 69/100 among other emerging companies.
Cryoport Inc spent $17.0M on research and development in fiscal year 2025, which was 8.0% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Cryoport Inc scores 31/100 among other emerging companies.
Cryoport Inc reported revenue of $176.2M in fiscal year 2025, against $156.8M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Cryoport Inc scores 46/100 among other emerging companies.
Cryoport Inc's operations used $8.6M of cash in fiscal year 2025, against $16.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Cryoport Inc scores 2/100 among other emerging companies.
Cryoport Inc's cash, cash equivalents and investments came to $411.2M at the end of fiscal year 2025, against $262.4M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Cryoport Inc scores 70/100 among other emerging companies.
Cryoport Inc scores 1.01, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($783.5M) relative to total liabilities ($262.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cryoport Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Cryoport Inc used $0.11 of operating cash (-$8.6M OCF vs $78.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Cryoport Inc reported an operating loss of $36.8M against $2.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cryoport Inc generated $49.0M in revenue in Q2 2026. This represents an increase of 7.7% from the same quarter a year earlier. Against the prior quarter it is up 2.5%.
Cryoport Inc's EBITDA was -$3.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 46.6% from the same quarter a year earlier. Against the prior quarter it is down 7.4%.
Cryoport Inc reported -$8.3M in net income in Q2 2026. This represents a decrease of 107.6% from the same quarter a year earlier. Against the prior quarter it is up 21.7%.
Cryoport Inc earned -$0.20 per diluted share (EPS) in Q2 2026. This represents a decrease of 109.4% from the same quarter a year earlier. Against the prior quarter it is up 20.0%.
Cash & Balance Sheet
Cryoport Inc recorded an outflow of $8.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 31.8% from the same quarter a year earlier. Against the prior quarter it is down 27.6%.
Cryoport Inc held $269.3M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Cryoport Inc's gross margin was 46.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.8 percentage points.
Cryoport Inc's operating margin was -20.5% in Q2 2026, reflecting core business profitability. This is up 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.4 percentage points.
Cryoport Inc's net profit margin was -16.9% in Q2 2026, showing the share of revenue converted to profit. Against the prior quarter it is up 5.2 percentage points. No change is given against Q2 2025: its reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Cryoport Inc's ROE was -1.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 22.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.
Capital Allocation
Cryoport Inc invested $4.9M in research and development in Q2 2026. This represents an increase of 17.8% from the same quarter a year earlier. Against the prior quarter it is up 24.2%.
Cryoport Inc invested $9.1M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 109.2% from the same quarter a year earlier. Against the prior quarter it is down 8.8%.
Not reported for Q2 2026.
CYRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.0M+7.7% | $47.8M+16.5% | $45.5M+9.6% | $44.2M+15.4% | $45.5M+14.5% | $41.0M+10.1% | $41.5M | $38.3M-31.8% |
| Cost of Revenue | $26.1M+8.6% | $25.9M+15.6% | $23.7M+8.1% | $22.9M+9.7% | $24.1M+9.2% | $22.4M+0.8% | $22.0M | $20.9M-34.5% |
| Gross Profit | $22.8M+6.8% | $21.9M+17.6% | $21.7M+11.4% | $21.3M+22.3% | $21.4M+21.0% | $18.6M+23.7% | $19.5M | $17.4M-28.1% |
| R&D Expenses | $4.9M+17.8% | $3.9M-0.7% | $4.5M+7.5% | $4.5M+8.8% | $4.1M-11.4% | $3.9M-17.2% | $4.2M | $4.2M-19.3% |
| SG&A Expenses | $28.0M+4.1% | $27.6M+26.1% | $27.3M-2.9% | $26.7M+0.2% | $26.9M-1.2% | $21.9M-21.3% | $28.1M | $26.7M-26.0% |
| Operating Income | -$10.0M-4.0% | -$9.6M-33.6% | -$10.0M+21.3% | -$9.9M+25.8% | -$9.6M+87.6% | -$7.2M+58.9% | -$12.7M | -$13.4M+20.8% |
| EBITDA | -$3.5M-46.6% | -$3.2M-810.6% | -$3.7M+24.2% | -$3.5M+36.7% | -$2.4M+96.7% | $452K+104.5% | -$4.9M | -$5.6M+44.5% |
| Interest Expense | $518K-16.2% | $432K-25.9% | $634K+22.9% | $526K-40.4% | $618K-50.2% | $583K-56.4% | $516K | $882K-35.0% |
| Income Tax | $505K+84.3% | $108K-53.8% | $1.1M+940.3% | $165K-47.8% | $274K+315.2% | $234K+110.8% | -$134K | $316K-32.9% |
| Net Income | -$8.3M-107.6% | -$10.5M+12.0% | -$11.6M+37.7% | -$6.9M-962.5% | $108.9M+239.6% | -$12.0M+36.6% | -$18.7M | $805K+106.1% |
| EPS (Basic) | -$0.20-109.4% | -$0.25+10.7% | -$0.28+33.3% | -$0.18-800.0% | $2.13+231.5% | -$0.28+34.9% | -$0.42+68.2% | -$0.02+93.5% |
| EPS (Diluted) | -$0.20-109.4% | -$0.25+10.7% | -$0.28+33.3% | -$0.18-800.0% | $2.13+231.5% | -$0.28+34.9% | -$0.42+68.2% | -$0.02+93.5% |
| Diluted Shares (Avg) | 50M+0.4% | 50M-0.1% | N/A | 50M+1.4% | 50M+1.8% | 50M+1.9% | N/A | 49M+1.1% |
CYRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $756.2M-2.3% | $763.6M+9.1% | $765.0M+8.7% | $774.3M+10.3% | $773.9M-9.2% | $699.8M-25.8% | $703.5M-26.5% | $701.8M-29.9% |
| Current Assets | $460.2M-6.0% | $470.5M+14.4% | $476.2M+39.4% | $484.8M+38.4% | $489.5M-2.5% | $411.3M-21.8% | $341.6M-36.2% | $350.3M-36.2% |
| Cash & Equivalents | $269.3M+10.6% | $272.9M+655.9% | $250.5M+633.8% | $255.8M+715.6% | $243.4M+612.1% | $36.1M-8.1% | $34.1M-3.0% | $31.4M-47.3% |
| Short-Term Investments | $127.4M-30.2% | $130.7M-37.1% | $160.7M-25.8% | $165.5M-27.4% | $182.6M-52.0% | $207.9M-47.9% | $216.5M-47.3% | $228.0M-43.9% |
| Inventory | $21.5M-6.6% | $21.8M-6.8% | $23.2M+8.0% | $23.3M-1.0% | $23.0M-2.4% | $23.3M-6.7% | $21.5M-18.0% | $23.6M-19.1% |
| Accounts Receivable | $36.5M+9.1% | $39.0M+37.5% | $33.4M+31.8% | $34.9M-19.7% | $33.4M-16.8% | $28.4M-31.2% | $25.3M-39.9% | $43.5M+2.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $22.1M+17.9% | $22.1M+5.6% | $22.4M+8.9% | $22.4M-58.5% | $18.7M-64.3% | $21.0M-80.5% | $20.6M-73.1% | $54.1M-63.7% |
| Total Liabilities | $265.5M+2.7% | $268.6M-10.8% | $262.4M-13.0% | $261.1M-7.8% | $258.5M-42.8% | $301.0M-36.0% | $301.6M-35.7% | $283.2M-38.9% |
| Current Liabilities | $221.0M+633.1% | $224.9M+203.8% | $219.0M+239.2% | $30.7M-50.0% | $30.1M-49.7% | $74.0M+51.1% | $64.6M+41.6% | $61.4M+36.8% |
| Non-Current Liabilities | $44.5M-80.5% | $43.8M-80.7% | $43.3M-81.7% | $230.3M+3.9% | $228.4M-41.8% | $227.0M-46.2% | $237.0M-44.0% | $221.8M-47.0% |
| Total Equity | $490.7M-5.5% | $495.0M+24.1% | $502.6M+25.1% | $513.3M+22.6% | $519.1M+29.7% | $398.8M-15.5% | $401.9M-17.8% | $418.6M-22.1% |
| Retained Earnings | -$707.7M-5.9% | -$699.4M+9.1% | -$688.9M+9.0% | -$675.2M+8.6% | -$668.2M+9.6% | -$769.2M-16.3% | -$757.2M-17.9% | -$738.5M-27.3% |
Not reported in any period shown, so not listed: Long-Term Debt.
CYRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.1M+115.4% | $3.7M+186.0% | $919K+116.8% | $2.2M+389.5% | -$7.3M+8.5% | -$4.3M-33.0% | -$5.5M | $447K+122.8% |
| Depreciation & Amortization | $6.6M-9.7% | $6.4M-16.3% | $6.4M-19.5% | $6.4M-18.1% | $7.3M-3.5% | $7.6M+2.4% | $7.9M | $7.8M+13.4% |
| Stock-Based Compensation | $2.4M+17.5% | $2.4M-21.8% | N/A | $2.5M-37.7% | $2.0M-51.3% | $3.1M-34.3% | N/A | $4.1M-32.1% |
| Capital Expenditures | $9.1M+109.2% | $10.0M+215.1% | $5.5M+4.8% | $3.5M-18.5% | $4.4M+14.8% | $3.2M-20.9% | $5.2M | $4.2M-52.7% |
| Free Cash Flow | -$8.0M+31.8% | -$6.2M+16.8% | -$4.5M+57.5% | -$1.3M+66.6% | -$11.7M+1.0% | -$7.5M-3.3% | -$10.7M | -$3.8M+65.3% |
| Investing Cash Flow | -$5.8M-102.5% | $18.7M+216.1% | $56K-98.4% | $14.3M-90.7% | $230.0M+1626.9% | $5.9M-8.1% | $3.5M | $153.6M+729.7% |
| Financing Cash Flow | $653K+104.1% | $85K+145.0% | -$2.2M-207.0% | -$2.9M+98.2% | -$15.9M-81.0% | -$189K-136.9% | $2.0M | -$155.3M-523.9% |
| Share Buybacks | N/A | N/A | $2.0M | $3.7M | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
CYRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 46.6%-0.4pp | 45.9%+0.4pp | 47.8%+0.7pp | 48.2%+2.7pp | 47.0%+2.6pp | 45.4%+5.0pp | 47.0% | 45.5%+2.3pp |
| Operating Margin | -20.5%+0.7pp | -20.1%-2.6pp | -22.1%+8.7pp | -22.4%+12.5pp | -21.2% | -17.5%+29.4pp | -30.8% | -34.9%-4.8pp |
| Net Margin | -16.9% | -22.1%+7.1pp | -25.6%+19.4pp | -15.7%-17.8pp | 239.5% | -29.2%+21.5pp | -45.1% | 2.1%+25.7pp |
| Return on Equity | -1.7%-22.7pp | -2.1%+0.9pp | -2.3%+2.3pp | -1.4%-1.5pp | 21.0%+40.5pp | -3.0%+1.0pp | -4.6% | 0.2%+2.7pp |
| Return on Assets | -1.1%-15.2pp | -1.4%+0.3pp | -1.5%+1.1pp | -0.9%-1.0pp | 14.1%+23.2pp | -1.7%+0.3pp | -2.7% | 0.1%+1.4pp |
| Current Ratio | 2.08-14.2x | 2.09-3.5x | 2.17-3.1x | 15.77+10.1x | 16.24+7.9x | 5.56-5.2x | 5.29-6.4x | 5.70-6.5x |
| Debt-to-Equity | 0.540.0x | 0.54-0.2x | 0.52-0.2x | 0.51-0.2x | 0.50-0.6x | 0.75-0.2x | 0.75-0.2x | 0.68-0.2x |
| Asset Turnover | 0.060.0x | 0.060.0x | 0.060.0x | 0.060.0x | 0.060.0x | 0.060.0x | 0.06 | 0.050.0x |
| FCF Margin | -16.3%+9.4pp | -13.1%+5.2pp | -10.0%+15.8pp | -2.9%+7.0pp | -25.7%+4.0pp | -18.3%+1.2pp | -25.8% | -9.9%+9.6pp |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Cryoport Inc CYRX | FY2025 | $176.2M | $78.3M | 44.4% | $783.5M | 53/100 |
| Radiant Logistic RLGT | FY2025 | $902.7M | $17.3M | 1.9% | $395.3M | 40/100 |
| Forward Air FWRD | FY2025 | $2.5B | -$104.0M | -4.2% | $604.3M | 31/100 |
| Pitney Bowes PBI | FY2025 | $1.9B | $144.7M | 7.6% | $2.4B | 16/100 |
| BingEx FLX | FY2025 | $570.9M | $15.6M | 2.7% | $139.7M | 38/100 |
| Proficient Auto Logistics Inc PAL | FY2025 | N/A | -$36.0M | N/A | $143.6M | — |
Where Cryoport Inc Ranks
Frequently Asked Questions
What is Cryoport Inc's annual revenue?
Cryoport Inc (CYRX) reported $176.2M in total revenue for fiscal year 2025. This represents a 12.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cryoport Inc's revenue growing?
Cryoport Inc (CYRX) revenue grew by 12.4% year-over-year, from $156.8M to $176.2M in fiscal year 2025.
Is Cryoport Inc profitable?
Yes, Cryoport Inc (CYRX) reported a net income of $78.3M in fiscal year 2025, with a net profit margin of 44.4%.
What is Cryoport Inc's EBITDA?
Cryoport Inc (CYRX) had EBITDA of -$9.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cryoport Inc's gross margin?
Cryoport Inc (CYRX) had a gross margin of 47.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cryoport Inc's operating margin?
Cryoport Inc (CYRX) had an operating margin of -20.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cryoport Inc's net profit margin?
Cryoport Inc (CYRX) had a net profit margin of 44.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cryoport Inc's return on equity (ROE)?
Cryoport Inc (CYRX) has a return on equity of 15.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cryoport Inc's free cash flow?
Cryoport Inc (CYRX) recorded an outflow of $25.0M in free cash flow during fiscal year 2025. This represents a 25.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cryoport Inc's operating cash flow?
Cryoport Inc (CYRX) recorded an outflow of $8.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cryoport Inc's total assets?
Cryoport Inc (CYRX) had $765.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cryoport Inc's capital expenditures?
Cryoport Inc (CYRX) invested $16.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cryoport Inc spend on research and development?
Cryoport Inc (CYRX) invested $17.0M in research and development during fiscal year 2025.
What is Cryoport Inc's current ratio?
Cryoport Inc (CYRX) had a current ratio of 2.17 as of fiscal year 2025, which is generally considered healthy.
What is Cryoport Inc's debt-to-equity ratio?
Cryoport Inc (CYRX) had a debt-to-equity ratio of 0.52 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cryoport Inc's return on assets (ROA)?
Cryoport Inc (CYRX) had a return on assets of 10.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cryoport Inc's P/E ratio?
Cryoport Inc (CYRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $783.5M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cryoport Inc's price-to-sales ratio?
Cryoport Inc (CYRX) trades at 4.2x sales, its market capitalization divided by revenue of $186.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $783.5M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cryoport Inc's Altman Z-Score?
Cryoport Inc (CYRX) has an Altman Z-Score of 1.01, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cryoport Inc's Piotroski F-Score?
Cryoport Inc (CYRX) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cryoport Inc's earnings high quality?
For every $1 of reported earnings, Cryoport Inc (CYRX) used $0.11 of operating cash (-$8.6M OCF vs $78.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cryoport Inc cover its interest payments?
Cryoport Inc (CYRX) reported an operating loss of $36.8M against $2.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Cryoport Inc?
Cryoport Inc (CYRX) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.